Australian LGP in Cannabis flower deal with Medezin

A FIVE-YEAR exclusive pharmaceutical distribution agreement has been signed between South West-based Little Green Pharma (LGP) and Medezin for the distribution of cannabis medicines into Poland.

Medezin is a subsidiary of Pelion SA – the largest operator in the Polish and Lithuanian healthcare sector – and is now the exclusive partner for the distribution of LGP’s medicinal cannabis oil and high tetrahydrocannabinol (THC) flower products in Poland.

Medezin is targeting the sale of products equivalent to at least 20 per cent of the Polish medicinal cannabis oil market and at least 10pc of the Polish high-THC medicinal cannabis flower Market.

LGP managing director Fleta Solomon said their distribution agreement with Medezin reflects the company’s strategic ambition to acquire and maintain a substantial share of the total addressable market in each jurisdiction it supplies.

“We are very pleased to have partnered with Medezin, a highly experienced and large-scale pharmaceutical distributor servicing the Polish market, to help us achieve this goal,” Ms Solomon said

The agreement is for a term of five years beginning on the date of grant of the first marketing authorisation and will automatically renew for successive one-year periods unless terminated.

The parties have already substantially progressed the first marketing authorisation dossier for LGP’s medicinal cannabis flower product.

The Polish market relies solely on imported cannabis medicines, with medicinal cannabis flower products retailing at between 650-700 Polish zloty, or $226 to $244 for 10 grams.


Our privacy policy